Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05028933
Other study ID # IMC001-CT04
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 30, 2021
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source Zhejiang University
Contact Bowen Peng
Phone +86 18870300543
Email bowen.peng@immunofoco.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase I Clinical Study of Autologous T cells modified with chimeric antigen receptor targeting EpCAM ( EPCAM CAR-T) in Patients with malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) .


Description:

This is a phase I open-label, single and multiple infusion, dose escalation/cohort expansion study to evaluate the safety, cell pharmacokinetics, and preliminary efficacy of EPCAM CAR-T, infused intravenously in subjects who have been diagnosed with advanced malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) and refractory or intolerant to current standard systemic treatment. Primary objectives: •To evaluate the safety and tolerability of EPCAM CAR-T infused intravenously at escalating doses in patients with advanced malignant tumors of the digestive system. Secondary objectives: 1. The treatment of EpCAM CAR-T for patients with advanced digestive system malignancies, according to the dose-limiting toxicity and clinical response, including Possible side effects, determine the maximum tolerated dose (MTD), extended recommended dose (RDE) and/or recommended phase II dose (RP2D). 2. Assess the correlation between the pharmacodynamic (PD) biomarkers of IMC001 and clinical efficacy; EpCAM CAR-T expands and persists in vivo Correlation between sexual and pharmacodynamic (PD) biomarkers and adverse events. 3. To evaluate the preliminary anti-tumor efficacy of EpCAM CAR-T in patients with advanced digestive system malignancies. According to the evaluation criteria for the efficacy of solid tumors (RECIST) Version V.1.1, Evaluation Criteria for Efficacy of Immunotherapy for Solid Tumors (iRECIST), using objective response rate(ORR), duration of remission (DOR), disease control rate (DCR) and progression-free survival (PFS) description preliminary Anti-tumor activity. 4. The incidence of treatment-related adverse events. Exploratory purpose: 1. Assess changes in immune status of EPCAM CAR-T treatment. 2. Assess the change of CTC in the peripheral blood of patients and the clearance effect of CAR-T cell treatment on CTC.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date December 31, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age between 18 and 70 years old (including boundary value), both male and female. 2. The first stage requires patients with malignant tumors of the digestive system (including advanced gastric cancer, advanced colorectal cancer, advanced pancreatic cancer, advanced liver cancer) who have failed previous standard treatments and have no other feasible effective treatment methods. The documents for the diagnosis of advanced digestive system malignancies include imaging reports (CT/MRI) or pathological examination results. The second stage requires patients with liver metastases of advanced digestive system malignancies (including gastric cancer liver metastasis, colorectal cancer liver metastasis, and pancreatic cancer liver metastasis) who have previously failed standard treatment and have no other feasible effective treatment methods. The investigator can judge it. Perform radiofrequency/microwave ablation therapy. Documents for diagnosing liver metastases from advanced digestive system malignancies include imaging reports (CT/MRI) or pathological examination results. 3. The subject's expected survival period is =12 weeks. 4. According to the RECIST V.1.1 standard, subjects participating in the first phase of dose escalation must have at least one target lesion that can be evaluated stably. Participants participating in the second phase of EpCAM CAR-T infusion therapy combined with local radiofrequency/microwave ablation therapy must have at least one non-target disease in the liver that is suitable for radiofrequency/microwave ablation therapy. 5. The histological staining of EpCAM in the biopsy tumor tissue sample is positive. 6. Subjects in the second stage require Child-Pugh classification of liver function as A or B (score = 7 points). 7. ECOG stamina score 0~1. 8. The subject has sufficient organ and bone marrow function. Laboratory screening must meet the following standards (refer to NCI CTCAE 5.0). All laboratory test results should be within the following stable range and there is no continuous supportive treatment. 1. Blood test: white blood cell WBC=1.5×10^9/L; platelet count PLT =60×10^9/L; hemoglobin content Hb =8.0g/dL; lymphocyte LYM=0.4×10^9/L; 2. Blood biochemistry: serum creatinine=1.5×ULN, if serum creatinine>1.5×ULN, creatinine clearance rate>50mL/min (calculated according to Cockcroft-Gault formula); serum total bilirubin=1.5×ULN, alanine Aminotransferase (ALT)=2×ULN, aspartate aminotransferase (AST)=2×ULN (ALT=5×ULN in patients with liver metastasis or liver cancer, AST=5×ULN). 3. Amylase and lipase = 1.5 × ULN; 4. Routine urine examination: urine protein <2+ 9. The left ventricular ejection fraction (LVEF)>45% in cardiac color Doppler ultrasound examination within one month. 10. Fertility status: female patients of childbearing age or male patients whose sexual partners are females of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last cell infusion (females of childbearing age include premenopausal women and premenopausal women). Women within 2 years after menopause). 11. The subject must sign and date a written informed consent form. 12. The subject must be willing and able to comply with the predetermined treatment plan, laboratory examination, follow-up and other research requirements. Exclusion Criteria: Subjects who meet any of the following conditions cannot be selected for this study; 1. Women during pregnancy and lactation. 2. Known history of human immunodeficiency virus (HIV) infection; acute or chronic active hepatitis B (HBsAg positive); acute or chronic active hepatitis C (HCV antibody positive). Syphilis antibody is positive; Epstein-Barr virus DNA quantitative> 500 copies; Cytomegalovirus (CMV) infection (IgM positive). 3. Severe infections that are active or poorly clinically controlled. 4. At present, there is a heart disease requiring treatment or a poorly controlled hypertension (defined as systolic blood pressure =140 mmHg and/or diastolic blood pressure >90 mmHg after treatment with standardized antihypertensive drugs). 5. The presence of any of the following cardiac clinical symptoms or diseases: 1. Unstable angina; 2. Myocardial infarction occurred within 1 year; 3. ECG at rest QTc>450ms (male) or QTc>470ms (female); 4. The resting state ECG examination found abnormalities of important clinical significance (such as abnormal heart rate, conduction, morphological characteristics, etc.) or complete left bundle branch block or third-degree heart block or second-degree heart block or PR Interval> 250ms; 5. There are factors that increase the risk of QTc prolongation and abnormal heart rate, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or sudden death of unexplained family members under 40 years old, or prolonged periods Period concomitant medication. 6. Abnormal blood coagulation function (INR>1.5×ULN), bleeding tendency or receiving thrombolysis or conventional anticoagulation therapy (such as warfarin or heparin), patients need long-term antiplatelet therapy (aspirin, dose> 300mg/day; Clopidogrel, dose>75mg/day). 7. Subjects who need to use corticosteroids or other immunosuppressive drugs for systemic therapy during the treatment period. 8. Before treatment, blood oxygen saturation =95% (referring to pulse oxygen detection). 9. Have received systemic steroids equivalent to >15 mg/day of prednisone within 2 weeks before apheresis, except for inhaled steroids. 10. Before the pretreatment of chemotherapy for removing lymphocytes, the subject developed a new arrhythmia, including but not limited to arrhythmia that cannot be controlled with drugs, hypotension that requires vasopressor, bacteria, fungi, or intravenous antibiotics that require intravenous antibiotics. Viral infection. Subjects who use test antibiotics to prevent infection are up to the investigator to determine whether participants can continue to participate in the test. 11. Known past or current hepatic encephalopathy requiring treatment; patients with current or history of central nervous system disease, such as epileptic seizures, cerebral ischemia/hemorrhage, dementia, cerebellar disease or any associated central nervous system involvement Autoimmune disease; central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, and the investigator judged that it is not suitable for inclusion in the group. 12. The results of the imaging examination of the subjects in the second stage: the liver is replaced by tumors =50%, or the main portal vein tumor thrombus, or the tumor thrombus invades the mesenteric vein/inferior vena cava; or there are central or extensive non-metastatic lesions . 13. Patients who have had other malignant tumors before or at the same time, with the following exceptions: - Adequately treated basal cell or squamous cell carcinoma (enough wound healing is required before being enrolled in the study); - Cervical cancer or breast cancer in situ, after curative treatment, there is no sign of recurrence at least 3 years before the study; - The primary malignant tumor has been completely removed and completely remitted for =5 years. 14. Have received other CAR-T treatments and TCR-T treatments in the past. 15. Received anti-PD-1/PD-L1 monoclonal antibody treatment within 4 weeks before apheresis. 16. Subjects who have received other gene therapy in the past. 17. Subjects with severe mental disorders. 18. Participated in other clinical studies in the past month. 19. The researcher assesses that the subject is unable or unwilling to comply with the requirements of the research protocol. 20. The subject withdrew from the study due to various reasons and could not participate in the study again.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EPCAM CAR-T
Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion

Locations

Country Name City State
China First affiliated hospital, School of Medicine, Zhejiang University Hangzhou
China Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limited toxicity (DLT) Safety 28 days
Primary Maximum Tolerated Dose(MTD) Tolerability evaluation 28 days
Primary Adverse Event(AE) Incidence rate 28 days
Secondary Number of Cells Pharmacokinetics is the "Implantation endpoint" which is defined as the number of copies of the IMC001 DeoxyriboNucleic Acid(DNA)in peripheral blood detected at each visit after infusion until any two consecutive test results are negative or below the detection limit. Duration of IMC001 Cell persistence is the period from the day of infusion to the first negative test result or result lower than the detection limit 52 weeks
Secondary Treatment Emergent Adverse Events(TEAE) Incidence rate Through study completion, an average of 3 years
Secondary Antitumor efficacy-objective response rate (ORR) The period from the first evaluation of CR or PR to the first evaluation of PD or death of any cause.
The period from the first evaluation of CR or PR to the first evaluation of PD or death of any cause.
Through study completion, an average of 3 years
Secondary Antitumor efficacy-Progression-free survival (PFS) The period from the day when the subject receives the first study treatment to the first recorded tumor progression(whether treated or not) or death of any cause, which occurs first Through study completion, an average of 3 years
Secondary Antitumor efficacy-Duration of response (DOR) The period from the first evaluation of CR or PR to the first evaluation of PD or death of any cause. Through study completion, an average of 3 years
Secondary Antitumor efficacy-Overall survival (OS) The period from the first study treatment to any cause of death Through study completion, an average of 3 years
Secondary Antitumor efficacy-Disease control rate (DCR) The number of cases in which response (PR + CR) and stable disease (SD) are achieved from the start of cell infusion/the total number of evaluable cases (%). Through study completion, an average of 3 years
Secondary Number of circulating tumor cells (CTC) in peripheral blood The number of CTC before and after treatment was evaluated Through study completion, an average of 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05057845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT02632006 - Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT02638857 - Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT00752063 - Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma Phase 2
Completed NCT00517920 - Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT05797805 - A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Active, not recruiting NCT05070156 - B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Early Phase 1
Not yet recruiting NCT06092112 - A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma Early Phase 1
Recruiting NCT01214343 - Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC Phase 3
Completed NCT00999882 - Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients Phase 1
Withdrawn NCT00756782 - A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT00534664 - Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04503902 - Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Terminated NCT04777708 - BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Early Phase 1
Completed NCT04072679 - Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma Phase 1
Suspended NCT04066660 - Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) N/A
Withdrawn NCT05592197 - Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT N/A
Completed NCT02528643 - A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT04294498 - Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection Phase 2